Origin of the Fasting Mimicking Diet & the path to broader clinical acceptance | Valter Longo
[Rhonda]: So, you were talking about this
fasting-mimicking diet in humans this clinical
study in humans that you have a pilot trial
that you had done in humans, where you’re…
So, with the mouse studies into fasting, and
their autophagy in the regenerating of the
stem cells, and, you know, that stuff’s all
very exciting and has relevance for, you know,
for cancer, and for aging, in general.
But how can you translate like a 48-hour fast
to humans, and is that, sort of, why you’ve
come up with this fasting-mimicking diet because
the amount of time would have to be like a
week, or five days, or something that seems
a lot more difficult for humans to do?
So, it’s not just about difficulty, it’s also
And so, when we first started with the fasting
in cancer patients, basically the patients
didn’t want to do it, and the doctors didn’t
want to do it, so it’s really a struggle.
And it took us forever here at the Norris
Cancer Center, our own University, to get
18 patients to go through it, it took us like
five or six years.
So, it was very difficult.
And then, we started asking people, “What
if we give you a fasting-mimicking diet?”
And we started asking doctors, “What if we
give patients a box, and it has all the foods
that they need?”
So, it’s more of a medicine, right?
You just hand over to the patient a medicine.
And then, everything turned around, so people
were much more likely to do it, they felt
[Rhonda]: It’s more compliance.
[Valter]: …psychologically, we give them
something, they also, of course, they’re eating
almost normal…I mean, normally in the sense
at the right times, they’re not eating normally,
but obviously, the diet is very different
than the normal diet.
And the doctors felt so good about it.
So, I think, it was really important to get
to get the fasting-mimicking diet going, and,
you know, so now we have a number of trials
in cancer patient, in diabetes patients.
Soon enough, we’ll start with…well, we finished
one multiple sclerosis, and so, now, we’re
ready to start talking to the FDA about moving
to the next level.
I think people are underestimating the power
of this, and there’s good and bad, I guess,
but I think that it’s got a real potential
as we’re seeing now that we’re talking to
And now we’re seeing a lot of doctors, cardiologists,
and endocrinologists, gynecologists prescribing
Or recommending, and they’re not prescribing,
it’s not a drug.
But they’re recommending it to a patient,
and it’s been great, you know.
And now we have a couple of hundred doctors
that we’re been talking to see this group
of people changed from this drug-centered
mentality to, maybe there are things that
we didn’t realize could be very powerful,
and much more able to, again, let the body
And so, I would not be surprised if in 10
years, worldwide, these type of interventions
are gonna be standard in the doctor’s office.